Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597909 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00597909: Clinical Trial Phase 2 study, sponsored by Amgen.
NCT00597909 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00597909, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE).
Interventions
- DRUG sodium phenylacetate and sodium benzoate injection 10% / 10%
- DRUG placebo solution (10% dextrose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Why NCT00597909 stopped before completion
NCT00597909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which sodium phenylacetate and sodium benzoate injection 10% / 10% is the first listed.
NCT00597909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00597909 about?
NCT00597909 is a clinical study titled "Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy". The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE).
What is the current status of trial NCT00597909?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2007-12. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00597909?
The interventions under investigation include: sodium phenylacetate and sodium benzoate injection 10% / 10% (DRUG), placebo solution (10% dextrose) (DRUG).
Who is sponsoring clinical trial NCT00597909?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00597909's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia